Faricimab Treat-and-Extend for Diabetic Macular Edema
Authors:
Top Cited Papers
Open Access
- 28 December 2023
- journal article
- research article
- Published by Elsevier in Ophthalmology
- Vol. 131 (6) , 708-723
Abstract
No abstract availableKeywords
Funding Information
- F Hoffmann-La Roche Ltd
- F. Hoffmann-La Roche
This publication has 35 references indexed in Scilit:
- Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular EdemaOphthalmology, 2016
- Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literatureBritish Journal of Ophthalmology, 2016
- Angiopoietin 2 induces astrocyte apoptosis via αvβ5-integrin signaling in diabetic retinopathyCell Death & Disease, 2016
- Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular EdemaNew England Journal of Medicine, 2015
- Endothelial destabilization by angiopoietin-2 via integrin β1 activationNature Communications, 2015
- Angiopoietin 2 Induces Pericyte Apoptosis via α3β1 Integrin Signaling in Diabetic RetinopathyDiabetes, 2014
- Angiopoietin-2 Is Critical for Cytokine-Induced Vascular LeakagePLOS ONE, 2013
- Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signalingJournal of Clinical Investigation, 2012
- Angiopoietin-2 sensitizes endothelial cells to TNF-α and has a crucial role in the induction of inflammationNature Medicine, 2006
- Angiopoietin‐2 enhances retinal vessel sensitivity to vascular endothelial growth factorJournal of Cellular Physiology, 2004